Journal article
Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma
Annals of oncology, Vol.27(1), pp.165-172
01/2016
DOI: 10.1093/annonc/mdv486
PMCID: PMC4684152
PMID: 26487586
Abstract
T-cell malignancies are heterogeneous in their clinical presentation and pathology, and have a poor prognosis. New biomarkers are needed to predict prognosis and to provide insights into signal pathways used by these cells. The goal of this study was to evaluate pretreatment serum cytokines in patients with newly diagnosed T-cell neoplasms and correlate with clinical outcome.
We evaluated 30 cytokines in pretreatment serum from 68 untreated patients and 14 normal controls. Significantly elevated cytokines were correlated with patterns of abnormalities, event-free survival (EFS) and overall survival (OS).
Our data demonstrated significantly elevated levels (versus controls) of seven cytokines—epidermal growth factor (EGF), IL-6, IL-12, interferon gamma-induced protein (IP)-10, soluble interleukin (sIL)-2Rα, monokine induced by gamma interferon (MIG), and IL-1RA—in all T-cell neoplasms (P < 0.05). In the angioimmunoblastic subset, all seven cytokines except IP-10 and in the peripheral T-cell lymphoma (TCL)-not otherwise specified subset, only IP-10, sIL-2Rα, MIG, and IL-8 were statistically elevated compared with control. Of these, elevated cytokines all but EGF were predictive of an inferior EFS; IL-1RA, sIL-2Rα, and MIG predicted an inferior OS. In a multivariate analysis, sIL-2Rα [hazard ratio (HR) = 3.95; 95% confidence interval (CI) 1.61–8.38] and IL-1RA (HR = 3.28; 95% CI 1.47–7.29) levels remained independent predictors of inferior EFS. TCL cell lines secreted high levels of sIL-2Rα and expressed the IL-2Rα surface receptor.
This report describes the cytokines relevant to prognosis in patients with untreated TCL and provides the rationale to include serum IL-1RA and sIL-2Rα as biomarkers in future trials. Inhibition of these cytokines may also be of therapeutic benefit.
Details
- Title: Subtitle
- Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma
- Creators
- M. Gupta - Division of Hematology, Department of Internal Medicine, Mayo Clinic, RochesterM. Stenson - Division of Hematology, Department of Internal Medicine, Mayo Clinic, RochesterM. O'Byrne - Department of Health Sciences Research, Mayo Clinic, Rochester, USAM.J. Maurer - Department of Health Sciences Research, Mayo Clinic, Rochester, USAT. Habermann - Division of Hematology, Department of Internal Medicine, Mayo Clinic, RochesterJ.R. Cerhan - Mayo ClinicG.W. Weiner - University of IowaT.E. Witzig - Mayo Clinic
- Resource Type
- Journal article
- Publication Details
- Annals of oncology, Vol.27(1), pp.165-172
- Publisher
- Elsevier Ltd
- DOI
- 10.1093/annonc/mdv486
- PMID
- 26487586
- PMCID
- PMC4684152
- ISSN
- 0923-7534
- eISSN
- 1569-8041
- Grant note
- DOI: 10.13039/100000054, name: National Cancer Institute; DOI: 10.13039/100000002, name: National Institutes of Health, award: P50 CA97274, to MG, R01, CA127433, to TEW, R01 CA92153, to JRC; name: Predolin Foundation; DOI: 10.13039/100000054, name: National Cancer Institute; DOI: 10.13039/100000002, name: National Institutes of Health, award: P50 CA97274, to MG, R01, CA127433, to TEW, R01 CA92153, to JRC; name: Predolin Foundation
- Language
- English
- Date published
- 01/2016
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
- Record Identifier
- 9984360050602771
Metrics
9 Record Views